Type Public Founded 2 May 2001 Revenue 49.1 million SGD (2014) | Industry Health Care Services Headquarters Singapore | |
 | ||
Traded as CLGL SP (Bloomberg); P8A.SI (Reuters) Area served Singapore, Hong Kong, India, Indonesia, The Philippines (under Cordlife brand); China, Malaysia and Thailand (under other brands through investment stake) Key people Dr. Ho Choon Hou (Chairman)
Dr. Wong Chiang Yin (Group CEO) Products Cord blood banking, cord lining banking, metabolic screening and other products catering to the mother & child segment Stock price P8A (SGX) SGD 1.05 -0.03 (-2.31%)6 Mar, 4:41 PM GMT+8 - Disclaimer CEO Wong Chiang Yin (Jul 2016–) Profiles | ||
Sgx sector connect 2013 cordlife group limited 4 4
Incorporated in May 2001, Cordlife Group Limited ("Cordlife"), is a multi-product healthcare company catering to the mother and child segment and a provider of cord blood and cord lining banking services. It provides cord blood banking services in Singapore, Hong Kong, India, Indonesia and the Philippines.
Contents
- Sgx sector connect 2013 cordlife group limited 4 4
- Sgx sector connect 2013 cordlife group limited 3 4
- 2014 2012
- 2011 2008
- 2007 2001
- Cord blood banking
- Cord lining banking
- Newborn metabolic screening
- Singapore
- Hong Kong
- Indonesia
- India
- The Philippines
- China
- Malaysia
- References
In addition, Cordlife has a 10% direct stake in China Cord Blood Corporation ("CCBC"), a cord blood bank operator in China holding majority shares in the Beijing, Guangdong and Zhejiang Cord Blood Banks, and an approximately 24% share in Shandong Cord Blood Bank. In October 2013, Cordlife acquired a 19.92% stake, which was subsequently increased to approximately 31.81% in December 2013, in StemLife Berhad. Currently listed on the ACE Market of Bursa Malaysia, StemLife is a fully licensed cord blood banking facility with the Ministry of Health Malaysia.
Cordlife has been accredited since 2005 by AABB (formerly known as the American Association of Blood Banks), an association involved in the field of transfusion medicine and cellular therapies.
Sgx sector connect 2013 cordlife group limited 3 4
2014-2012
2011-2008
2007-2001
Cord blood banking
Cord blood banking refers to the collection at birth, processing, testing, cryopreservation and storage of stem cells from the umbilical cord blood. Cord blood, also called "placental blood", is blood that remains in the umbilical cord and placenta following the birth of a baby and after the umbilical cord is cut. During pregnancy, the umbilical cord functions as a lifeline between mother and child. After a baby's delivery, the cord blood present in the umbilical cord could offer hope for the child or members of the family. Cord blood is a rich source of haematopoietic stem cells (HSCs), which are primarily responsible for replenishing blood and regenerating the immune system.
Cordlife has already launched cord blood banking services in the following countries: Singapore, Hong Kong, India, Indonesia and the Philippines.
Cord lining banking
Cord lining banking refers to the collection, processing, testing, cryopreservation and storage of the lining from an umbilical cord. After the baby is delivered, the umbilical cord is cut and normally discarded with the placenta as medical waste until researchers became aware of its medical potential.
Cord lining contains both Epithelial (EpSCs) and Mesenchymal stem cells (MSCs). EpSCs form the soft tissues that connect, support, or surround other structures and organs of the body including cornea, skin, and liver. MSCs are the building blocks of structural tissues of our body such as bone, cartilage, muscle, fibrous tissues and fat.
Cordlife has already launched cord lining banking services in the following countries:
Newborn metabolic screening
Newborn metabolic screening screens for inborn errors of metabolism from urine samples that can impact the health of newborns. Metabolic disorders are usually not apparent at the time of birth. If left undiagnosed and untreated, the baby can suffer from neurological impairment and physical deformities.
Cordlife has already launched this newborn metabolic screening test (Metascreen) in the following countries:
Singapore
Cordlife Singapore is the country’s first private cord blood bank and the corporate headquarters of the Group. Situated at A’Posh Bizhub, Yishun, Cordlife Singapore’s fully owned 23,000 square feet processing and storage facility has a storage capacity of up to 650,000 cord blood units. Since 2005, Cordlife Singapore has been accredited by AABB. To date, Cordlife Singapore has successfully released seven cord blood units to its clients. In May 2013, Cordlife Technologies Pte Ltd (“CTPL”), a wholly owned subsidiary of the Group, launched cord lining banking service in Singapore.
Hong Kong
Launched in 2005, Cordlife (Hong Kong) Limited (“Cordlife Hong Kong”) is a wholly owned subsidiary of the Group. Cordlife Hong Kong moved into a new facility at the Hong Kong Science Park in 2010. The AABB & ISO certified facility has a storage capacity for 50,000 cord blood and umbilical cord units. In January 2011, Cordlife Hong Kong became the only private cord blood bank in Hong Kong to have released a cord blood unit for autologous (with one's own stem cells) transplantation to aid the treatment of neuroblastoma. In March 2011, Cordlife Hong Kong introduced CellOptima, a patented cord lining stem cell technology to extract Mesenchymal stem cells (MSCs) and Epithelial Stem Cells (EpSCs) from umbilical cord.. In 2014, Cordlife Hong Kong launched Metascreen, a newborn metabolic screening service, in Hong Kong.
Indonesia
Cordlife Indonesia has been providing cord blood processing and cyropreservation service to families in Indonesia since 2003. In October 2007, Cordlife Indonesia opened the first and only DEPKES licensed private cord blood banking facility in Indonesia. Located in Jakarta, Cordlife Indonesia’s ISO-certified processing and storage facility has a storage capacity of 30,000 cord blood units.
India
Cordlife Group owns a majority interest (85%) in Cordlife Sciences (India) Pvt. Ltd., (“Cordlife India”) through its wholly owned subsidiary CS Cell Technologies Pte. Ltd. Established in Kolkata, Cordlife India's cord blood facility has a storage capacity of up to 150,000 cord blood units. In July 2013, Cordlife India attained accreditation from AABB, an international, not-for-profit association representing individuals and institutions involved in the field of transfusion medicine and cellular therapies. The facility is also certified by ISO 9001:2008. In 2011, Cordlife India successfully released a stem cell unit for the first ever mixed stem cell transplant in India. Cordlife India introduced an advanced non-invasive newborn metabolic screening test called Metascreen in India in October 2013.
The Philippines
Cordlife Group owns a 99.99% interest in Cordlife Medical Phils., Inc. (“Cordlife Philippines”), through its wholly owned subsidiary CS Cell Technologies Pte. Ltd. Registered with the Department of Health, Cordlife Philippines' ISO-certified AABB-accredited facility cord blood processing and cryopreservation facility was officially launched in February 2010 with a storage capacity for 20,000 cord blood units. In August 2013, Cordlife Philippines officially launched its newest service, umbilical cord lining banking.
China
Cordlife Group owns a 10% interest in NYSE-listed China Cord Blood Corporation (“CCBC”). CCBC is the largest cord blood banking operator in China, with access to 4 of the 7 authorized cord blood banking licenses: Beijing, Guangdong, Zhejiang and Shandong. On 3 March 2014, Cordlife announced that it has signed a strategic alliance agreement with Cordlabs Asia (“CAP”) and China Cord Blood Corporation to expand cord lining storage services to certain territories in the PRC.
Malaysia
Malaysia cord blood banking operator StemLife is an associate company of Cordlife Group. Cordlife Group acquired a 19.92% stake in StemLife in October 2013, which was subsequently increased to approximately 31.81% in December 2013. Incorporated in 2001, StemLife is the first stem cell banking and therapeutics company in Malaysia. StemLife is currently listed on the ACE Market of Bursa Malaysia. StemLife operates its own 24-hour processing, testing, and cryopreservation facility in central Kuala Lumpur, Malaysia.